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Executive Summary
The Task Force to Study Cervical Cancer Prevention, Detection and Education (“Task
Force”) was established in the First Regular Session of the 122nd Legislature by Resolves 2005,
Chapter 121. The Task Force is authorized to meet over a two-year period to examine the
prevalence and incidence of cervical cancer in Maine, to review preventive strategies and new
technologies, to assess existing laws, programs and services, and, ultimately, to develop a
statewide cervical cancer prevention plan and strategies for plan implementation and
coordination. As created, the 16-member Task Force includes one member of the Senate, two
members of the House of Representatives, eight members representing different medical
organizations, associations and specialties, one member representing the health insurance
industry, one member representing communications consultants, one member representing
cervical cancer survivors and two representatives of the Maine Department of Health and Human
Services.
The Task Force was convened on November 16, 2005 and held a second meeting on
December 20, 2005. Task Force members received program information and data regarding
screening and treatment services within the state including the Maine Cancer Registry, the
Maine Breast and Cervical Health program and MaineCare coverage of cervical cancer services.
The Task Force also received information regarding clinical and technology issues relating to
cervical cancer screening.
In accordance with the authorizing legislation, the Task Force will not meet from
December 21, 2005 to April 25, 2006. To complete its work, the Task Force anticipates holding
2 meetings between April 26, 2005 and June 30, 2006 (the end of the state fiscal year 20052006) and 4 meetings between July 1, 2006 and November 1, 2006. The Task Force will utilize
its future meetings to:
•

Further examine key clinical and technological issues related to cervical cancer
prevention and detection;

•

Identify and address gaps in cervical cancer prevention, detection and education; and

•

Develop a statewide cervical cancer prevention plan and strategies for plan
implementation and coordination.

The Task Force will then submit its findings, recommendations and any proposed
legislation in its final report, due November 1, 2006, to the joint standing committee of the
legislature having jurisdiction over health and human services matters.
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I. Introduction
The Task Force to Study Cervical Cancer Prevention, Detection and Education (“Task
Force”) was established in the First Regular Session of the 122nd Legislature by Resolves 2005,
Chapter 121. A copy of the law is attached in Appendix A. As created, the 16-member Task
Force includes one member of the Senate, two members of the House of Representatives, eight
members representing different medical organizations, associations and specialties, one member
representing the health insurance industry, one member representing communications
consultants, one member representing cervical cancer survivors and two representatives of the
Maine Department of Health and Human Services. The Task Force membership roster is listed in
Appendix B.
The Task Force was established to examine the prevalence and incidence of cervical
cancer in Maine, to review preventive strategies and new technologies, to assess existing laws,
programs and services, and, ultimately, to develop a statewide cervical cancer prevention plan
and strategies for plan implementation and coordination. Specifically, the Task Force was
charged with the following six duties:
1. Review statistical and qualitative data on the prevalence and incidence of cervical cancer
in Maine;
2. Review preventive strategies and new technologies, including newly introduced vaccines
and their effectiveness in preventing and controlling the risk of cervical cancer, as well as
their relative costs;
3. Identify and examine the strengths and limitations of existing laws, regulations, programs
and services regarding coverage and awareness of cervical cancer;
4. Consider reports and testimony from individuals, local health departments, communitybased organizations, voluntary health organizations and other public and private
organizations statewide to learn more about their contributions to cervical cancer
diagnosis, prevention and treatment and their ideas for improving prevention, diagnosis
and treatment in Maine;
5. Develop, in consultation with the Department of Health and Human Services, a statewide
comprehensive cervical cancer prevention plan and strategies for plan implementation
and for promoting the plan and awareness of the causes, risk factors, prevention, early
detection and treatment of cervical cancer to the general public, state and local elected
officials and various public and private organizations, associations, businesses, industries
and agencies; and
6. Recommend strategies for coordination and communication among state and local
agencies and organizations regarding their involvement in achieving the aims of the
cervical cancer prevention plan.
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Resolves 2005, chapter 121 requires the Task Force to submit two reports:
1. An initial report to the Joint Standing Committee on Health and Human Services and
to the Governor in December 2005;1 and
2. A final report to the Joint Standing Committee on Health and Human Services by
November 1, 2006.
The resolve authorizes the joint standing committee of the Legislature having jurisdiction over
health and human services matters in the First Regular Session of the 123rd Legislature to report
out legislation on cervical cancer prevention, detection and education.

II. Task Force Progress and Meetings
Appointments to the Task Force were completed on October 19, 2005, and the Task
Force convened for its first meeting on November 16, 2005. The Task Force held a second
meeting on December 20, 2005.
A. First Meeting of the Task Force
The first meeting focused on laying the foundation for the work of the Task Force. The
meeting included three main components:
1. A review of the authorizing legislation and Task Force goals,
2. An overview of cervical cancer initiatives within the Maine Department of Health
and Human Services, and
3. An opportunity to discuss and identify priorities for the Task Force within the context
of its required duties.
1. Authorizing Legislation and Task Force Goals
Task Force members reviewed the authorizing legislation, Resolves 2005, chapter 121,
with particular focus on the duties and reporting requirements described in the Introduction
above (see also Appendix A). Members discussed the motivation and underlying goals for the
Task Force and identified the following justifications for undertaking this work:
•

While Maine is doing relatively well in the areas of cervical cancer prevention,
detection and education, there is an opportunity for the State to further reduce the
rate of cervical cancer given the current technology and to move toward complete
eradication of cervical cancer with the development and introduction of new
technology, and

1

The deadline for the initial report in Resolves 2005, chapter 121, was December 7, 2005. The Task Force
requested an extension of the reporting deadline from the Legislative Council to December 23, 2005; that extension
was approved by the Council on November 28, 2005.
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•

There are gaps in the current system of cervical cancer prevention, detection and
education in the State that need to be addressed.

2. Cervical Cancer Initiatives within DHHS
The Task Force invited representatives of the Maine Department of Health and Human
Services to present information on the Maine Cancer Registry and the Maine Breast and Cervical
Health Program.
a. Maine Cancer Registry
The Maine Cancer Registry (MCR) is a statewide population-based cancer surveillance
system established by the Legislature in 1983 (22 MRSA, Chapter 255). MCR collects patient
demographic, diagnosis and initial treatment information on all cancer cases diagnosed in Maine,
except for basal cell and squamous cell carcinoma of the skin. Information is collected from
hospitals, health care facilities, physicians and other health care providers who diagnose or treat
cancer patients. The law requires these individuals and facilities to report new cases to the MCR
within 6 months of seeing the patient. MCR is partially funded by the National Program of
Cancer Registries, a program of the U.S. Department of Health and Human Services, Centers for
Disease Control and Prevention (CDC).
MCR issues a “Cancer Incidence and Mortality Report” which includes statistical
comparisons between cancer incidence and mortality rates in Maine and the nation for various
cancer types, including cervical cancer. This information is used to monitor and evaluate cancer
incidence trends in Maine, to identify areas in need of public health interventions and to improve
cancer prevention, treatment and control. The latest data from the MCR shows that the rates of
cervical cancer incidence and mortality in Maine are similar to the rest of the nation: 2
Table 1
Cervical Cancer Age-Adjusted Incidence and Mortality Rates

Year
2000
2001
2002

Incidence Rate
per 100,000
Maine
National
6.5
7.3
9.2
7.3
7.1
6.8

Mortality Rate
per 100,000
Maine
National
1.8
2.5
1.6
2.4
2.2
2.3

b. Maine Breast and Cervical Health Program

2

The differences in rates of cervical cancer incidence and mortality in Maine compared with the nation are not
statistically significant. The National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER)
collects cancer information from 13 population based registries representing approximately 14% of the U.S.
Population. Because the population in Maine is 98% white, the Maine Cancer Registry uses the SEER White data as
a national comparison.
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In 1990, Congress enacted the Breast and Cervical Cancer Mortality Prevention Act
which established the National Breast and Cervical Cancer Early Detection Program
(NBCCEDP), the first and only national cancer screening program. This program, which is
administered by CDC, provides free breast and cervical cancer screening and related diagnostic
services for low income and uninsured women. The federal law does not authorize the CDC to
pay for treatment services for those women diagnosed with breast or cervical cancer.
Maine is one of over 60 states and tribal organizations that has received funding from the
CDC to implement a comprehensive breast and cervical cancer program. Established in 1994,
the Maine Breast and Cervical Health Program (MBCHP) is administered through the Maine
Department of Health and Human Services in collaboration with Medical Care Development,
Inc. Key features of the program are as follows:
•

Funding. Currently, Maine receives $1.8 million annually from the CDC for this
program. These federal funds are supplemented with approximately $381,000 in
state General Fund dollars.

•

Eligibility. To be eligible for MBCHP, a woman must: be age 40 years and older;
have income at or below 250% of the federal poverty level; be uninsured or
underinsured; and be a resident of Maine or New Hampshire.3

•

Enrollment. Since its inception, MBCHP has enrolled over 15,000 women and
provided 23,349 Pap tests and diagnosed 57 cases of cervical cancer. As of
December 7, 2005, there were 5,321 women currently enrolled in MBCHP. Of
these women, 33% were 40-49 years of age, 64% were 50-59 years and 3% were
65 years or older. The MBCHP enrollment rate by county ranged from a low of
6.8% of eligible women enrolled in Cumberland County to a high of 38.5% of
eligible women enrolled in Washington County.4

•

Covered clinical services. For enrollees, the MBCHP provides an annual exam,
including a clinical breast exam, pelvic exam, Pap test and HPV testing. Cancer
treatment is not covered by MBCHP but, in most cases, is covered by MaineCare
(Medicaid) pursuant to the federal Breast and Cervical Treatment Act of 2000.

•

Service delivery system and outreach. MBCHP funds nearly 300 sites to provide
clinical and educational services. These include: primary care provider sites
which provide clinical exams and pap tests; other health care professionals who
provide diagnostic services on referral; laboratory facilities that provide cytology
and pathology services; and community partnerships that provide public
education and other support services. In 2005, the MBCHP distributed 70,000
program brochures and 1,900 posters to 441 sites across the state.

3

The CDC gives the option of eligibility starting at age 18; due to the limited funding for MBCHP and the
availability of family planning services for younger women, Maine decided to begin eligibility at age 40.
4
Source: Maine Department of Health and Human Services, Maine Breast and Cervical Health Program.
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3. Task Force Priorities
Throughout its first meeting, the Task Force relied on the expertise of its members to
identify priorities to guide the group in the remainder of its work to address cervical cancer
prevention, detection and education. At the meeting, members specifically identified the
following priorities:
•

Examine key clinical and technological issues related to cervical cancer
prevention and detection, as follows:
o
o
o
o

•

Review national clinical guidelines for cervical cancer screening,
Evaluate existing Pap test technologies: thin prep and traditional pap,
Examine HPV testing issues, and
Track the development of new HPV vaccines; and

Identify and address gaps in cervical cancer prevention, detection and education,
as follows:
o Develop strategies to address unmet needs of two distinct populations: (1)
women who are not getting screened, and (2) women who are screened but for
whom screening fails,
o Explore opportunities to address the needs of women under 40 years, who are
presently ineligible for MBCHP, and
o Assess existing public education and outreach strategies and develop new
strategies to improve access to screening and treatment services, including
outreach to immigrant and minority populations.

B. Second Meeting of the Task Force
The second meeting of the Task Force, on December 20, 2005, focused on clinical issues
relating to cervical cancer screening and gathering additional information on screening and
treatment services within the state, including MaineCare coverage of cervical cancer services.
1. Cervical Cancer Screening
a. Screening Guidelines
Task Force members reviewed and discussed the current cervical cancer screening
guidelines provided by three groups: (1) the American Cancer Society (ACS), (2) the U.S.
Preventive Services Task Force5 (USPSTF), and (3) the American College of Obstetricians and

5

The USPSTF, sponsored by the U.S. DHHS Agency for Healthcare Research and Quality (AHRQ), is an
independent panel of experts in primary care and prevention that reviews the scientific evidence of effectiveness
and develops recommendations for clinical preventive services.
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Gynecologists (ACOG). As shown in Table 2, the recommended starting point for screening is
similar across the three groups, but the recommendations for how often to screen for cervical
cancer and when to stop screening differ across the groups. Task force members noted that these
differences in the recommendations were not surprising given that each group had its own
process and methodology for developing its guidelines.
Table 2
Cervical Cancer Screening Guidelines6
U.S. Preventive
Services Task
Force
(Jan. 2003)
Within 3 years of
onset of sexual
activity or age 21,
whichever comes
first

American College
of Obstetricians
and Gynecologists
(Aug. 2003)
Approximately 3
years after onset of
sexual intercourse,
but no later than age
21

a) Annually
b) Every 2-3 years
for women ≥30 yrs
with 3 negative
cytology tests

At least every 3
years

a) Annually
b) Every 2-3 years
for women ≥30 yrs
with 3 negative
cytology tests

If liquid-based cytology test

a) Every 2 years
b) Every 2-3 years
for women ≥30 yrs
with 3 negative
cytology tests

Insufficient
evidence

a) Annually
b) Every 2-3 years
for women ≥30 yrs
with 3 negative
cytology tests

If HPV testing used

Every 3 years if
HPV negative,
cytology negative
Women ≥ 70 yrs
with ≥ 3 recent,
consecutive
negative tests and
no abnormal tests in
prior 10 years

Insufficient
evidence

Every 3 years if
HPV negative,
cytology negative
Inconclusive
evidence to
establish upper age
limit

Recommendation
When to Start Screening

Screening Interval
If conventional Pap smear test

When to Stop Screening

American Cancer
Society
(Nov. 2002)
Approximately 3
years after onset of
vaginal intercourse,
but no later than age
21

Women > 65 yrs
with negative tests,
who are not
otherwise at high
risk for cervical
cancer

b. Understanding Cervical Cancer Screening Failure
The Task Force reviewed information regarding the factors that contribute to the failure
of cervical cancer screening to prevent the development of cervical cancer. Given the existing
screening technology, it is estimated that 95% of cervical cancer could be prevented under
6

U.S. Department of Health and Human Services, Centers for Disease Control and Prevention,
http://www.cdc.gov/std/HPV/ScreeningTables.pdf
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perfect conditions.7 In reality, 30% of cervical cancer cases are not prevented as a result of
imperfections, or failures, in the screening system. Screening failures can be divided into two
major types:
1. Insufficient screening. Approximately 65-70% of screening failures are the result of
women not being screened, including women who are never screened and women who
are not meeting the recommended guidelines for onset and frequency of screening; and
2. False negative screening. Approximately 30-35% of screening failures are the result of
“false negative” screening, in which a woman is screened but still develops cervical
cancer.
c. Cervical Cancer Screening Technology – Conventional Pap Smear and Thin Prep
To understand the state of current cervical cancer screening technology, the Task Force
reviewed the differences between the conventional Pap smear and the newer ThinPrep Pap test.
A number of advantages of the ThinPrep technology were identified, including:




More effective than conventional Pap smear in detecting low-grade and high-grade
lesions (specifically squamous intraepithelial lesions, or SILs);
Provides higher quality sample than conventional Pap smear (ease of sample collection is
a contributing factor); and
The sample is good for 30 days and can be used for follow-up testing for Human
Papillomavirus (HPV) without requiring the patient to return for another test.

Despite the advantages of the ThinPrep Pap test, it was noted that the ThinPrep does cost
significantly more than the conventional Pap test and given the current lack of scientific
evidence as to whether the ThinPrep will result in reductions in cervical cancer mortality, it is
still unclear whether the additional cost is warranted. Nonetheless, it is clear that practitioners
are increasingly using the ThinPrep instead of the conventional Pap test.
2. HPV and Cervical Cancer
The Task Force also briefly reviewed the relationship between Human Papillomavirus
(HPV) and cervical cancer and issues related to HPV testing. Research has shown the presence
of HPV in over 93% of cervical cancers.8 Only certain types of HPV have been linked to the
development of cervical cancer, including HPV 16 which is estimated to account for 50% of
cervical cancer, and HPV 18, 31 and 45, which together are estimated to account for 30% of
cervical cancer.9 While HPV is known to lead to cervical cancer, it is important to note that
most HPV infections are “transient” and will resolve on their own without medical intervention
7

Presentation of Dr. Michael Jones to the Task Force on December 20, 2005.
National Cancer Institute. Cervical Cancer: Backgrounder.
http://rex.nci.nih.gov/massmedia/backgrounders/cervical.html
9
Shah, Keerti V. (1997). “Human Papillomaviruses and Anogential Cancers.” The New England Journal of
Medicine, 337(19), 1386-1388.
8
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and will not develop into cervical cancer.10 Because most cases of HPV will not lead to cervical
cancer, positive HPV test results provide less information (have less predictive value) than
negative HPV test results.
HPV testing is increasingly being used to further evaluate Atypical Squamous Cells of
Undetermined Significance (ASCUS) results from a routine Pap test and determine whether to
proceed to a colposcopy, a visual examination of the outer portion of the cervix using a
colposcope to magnify and illuminate the area. Other drivers behind the use of the HPV test
include its relatively high sensitivity for detection of high-grade intraepithelial lesion (HSIL) and
the opportunity it presents to extend the screening interval for women 30 years or older who
have a negative HPV test result (see Table 2).
3. HPV Vaccines
The Task Force reviewed information regarding the status of HPV vaccine development
and related issues. It is anticipated that the introduction of HPV vaccines may significantly
advance cervical cancer prevention. At the same time, it is important to recognize that there will
be a significant lag period between the introduction of the vaccines and a reduction in cervical
cancer mortality rates, due to the latency associated with this disease.
Two HPV vaccines are currently in the pipeline for licensure by the U.S. Food and Drug
Administration (FDA):


Gardasil, being developed by Merck, targets HPV types 6, 11, 16 and 18. Merck
submitted its Biologics License Application (BLA) to the FDA in December 2005; and



Cervarix, being developed by GlaxoSmithKline(GSK), targets HPV types 16 and 18.
Phase III clinical trials are currently in progress and GSK intends to submit its BLA in
2006.

Both Gardasil and Cervarix have been shown to be highly effective in preventing persistent HPV
infection and 100% effective in preventing HPV type-specific associated lesions.11 Task Force
members noted that while the efficacy of these vaccines is clear, acceptance of the vaccines
among health care providers, parents and patients is an important practical challenge that will
need to be addressed to fully realize the potential of these vaccines.
4. “At Your Cervix” Program
The Task Force invited Tri-County Health Services (TCHS) to present information
regarding its new cervical cancer prevention program, At Your Cervix. TCHS, a program of the
Western Maine Community Action agency, provides reproductive health services and education
to residents of Androscoggin, Franklin and Oxford counties. With a two-year grant from the
10

Presentation of Dr. Michael Jones to the Task Force on December 20, 2005.
Diane M. Harper, MD, MPH, MS. Presentation to “The Status Cervical Cancer Vaccine Research” conference,
Women’s Policy, Inc., Washington, DC, December 6, 2005.
11
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Maine Health Access Foundation, TCHS launched At Your Cervix in July 2005 to enhance and
expand its cervical cancer prevention effort. As part of At Your Cervix, TCHS has been able to:







Switch from conventional Pap tests to liquid based Pap tests at no extra charge to clients,
Provide HPV testing for all atypical Pap test results,
Provide significant discounts for colposcopy, cryosurgery and cervical biopsy
procedures,
Purchase equipment to perform colposcopies in all three counties,
Train a clinician in the Loop Electrical Excision Procedure (LEEP), a procedure to
remove tissue from the cervix, and
Initiate new community outreach services including providing information to local
providers (gynecologists and family practice physicians), distributing At Your Cervix
information along with heating assistance program applications and hiring a Somali
outreach worker for the Lewiston-Auburn area.
5. MaineCare Coverage of Cervical Cancer
a. Cervical Cancer Services and Expenditures

The Task Force invited representatives of DHHS to present information regarding
MaineCare services and expenditures related to cervical cancer. As summarized in Table 3,
DHHS provided data organized by diagnosis code (the client’s diagnosis) and other data
organized by procedure code (the clinical procedure performed).
Table 3
MaineCare Expenditures Related to Cervical Cancer
State Fiscal Year 200412

13

By Diagnosis Code (ICD-9)
Routine Pap/Gynecological exam
Treatment/Evaluation of Abnormal Pap
Human Papillomavirus (HPV)
Cervical cancer treatment or care
By Procedure Code
Cytopathology for Pap smear
Colposcopy/Biopsy/LEEP
HPV testing

# Distinct
Claims

# Distinct
Members

Total Paid

31,850
37,801
1,517
1,755

23,546
21,304
1,256
564

$1,510,609
$2,101,414
$131,101
$832,836

39,290
2,113
2,069

33,320
1,825
1,964

$579,418
$118,675
$27,642

b. MaineCare Coverage under the Treatment Act

12

Source: Maine Department of Human Services, MMDSS
ICD-9 stands for the International Classification of Diseases, 9th Revision, Clinical Modification, which is a
listing of diagnoses and identifying codes used by physicians for reporting patient diagnoses to health plans.

13
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In accordance with the federal Breast and Cervical Cancer Prevention and Treatment Act
of 2000 (the Treatment Act), Maine enacted Public Law 2001, chapter 439, Part TT to require
the state’s Department of Health and Human Services to amend its rules to provide full
MaineCare coverage to women diagnosed with breast or cervical cancer under the Maine Breast
and Cervical Health Program. Approximately two years following this rule change, Maine
applied for and received federal approval to also provide MaineCare coverage to those women
who are not enrolled in MBCHP but who: (a) meet MBCHP eligibility requirements and (b) are
diagnosed with breast or cervical cancer at a Federally Qualified Health Center participating in
the MBCHP,14 a less restrictive option allowed under the federal Treatment Act.
To be eligible for MaineCare under the above Treatment Act provisions, a woman must
be under age 65, not covered by credible health insurance, and have income less than 250% of
the federal poverty level.15 MaineCare coverage under these rules is continuous for one year as
long as the woman is receiving cancer treatment. Since 2001, 88 women with cervical cancer or
a pre-cancerous cervical cancer condition have been enrolled in MaineCare under these rules.
Of these women, 64% entered MaineCare with a diagnosis of cervical cancer and 36% entered
with a pre-cancerous condition.

III. Agenda for Future Work
In accordance with the authorizing legislation, the Task Force will not meet from
December 21, 2005 to April 25, 2006. To complete its work, the Task Force anticipates holding
2 meetings between April 26, 2005 and June 30, 2006 (the end of the state fiscal year 20052006) and 4 meetings between July 1, 2006 and November 1, 2006.
Task Force members have identified the following three areas to address at the next meeting:
•

Continue to monitor the development of cervical cancer vaccines and invite
representatives from the U.S. Centers for Disease Control and pharmaceutical companies
(Merck, GlaxoSmithKline) to brief the Task Force on the vaccines;

•

Examine available data on the geographic distribution of women in Maine who are not
receiving sufficient cervical cancer screening services (including follow-up services after
an abnormal Pap) and discuss potential strategies to reach these women; and

•

Examine available data from the Maine Health Data Organization on cervical cancer
screening and treatment service utilization and expenditures in both public and private
health care systems in Maine.

14

This change was motivated by LD 143, Resolve, to Improve Access to Breast and Cervical Cancer Treatment,
which was proposed in the 121st legislature. Ultimately, the LD 143 was not enacted after the department agreed to
make the changes without legislation.
15
Specifically the individual must have no “credible coverage” as defined in Section 2701(a) of the federal Public
Health Service Act.
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More broadly, the Task Force will utilize its future meetings to:
•

Further examine key clinical and technological issues related to cervical cancer
prevention and detection;

•

Identify and address gaps in cervical cancer prevention, detection and education; and

•

Develop a statewide cervical cancer prevention plan and strategies for plan
implementation and coordination.

The Task Force will then submit its findings, recommendations and any proposed legislation in
its final report, due November 1, 2006, to the joint standing committee of the legislature having
jurisdiction over health and human services matters.
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When making appointments to the task force, each appointing atttho rity shall ensure thul
appointees re nee! the composition of the State's popu lation with regard to elhni city, race and
age; and be it further

Sec. 3. Chair. Resolved : That the Senate member shall .<crve as cha ir and the iillit-namcd

I louse mcmher shall serve as vice-chair. <lnd be at further
Sec. 4. Appoi ntment s; cn n,·c11in g of task fo •·cc. Reso l,·cd: f hat ;til ;tppointtll~.>nts must be
made; no later than 30 days allcr the cffcctt vc el ate ofthts resolve The nppo intuag au thoriucs
sit<~ II not i f'y 1he l!x<.!cu tivc Dirccl()r of the Lcgisltt t ivc Council once all arpo intmctlt~ have been
compl eted. The ch:tir shell call and convene the first meeting of tile t:tsk force by August I ,
200 5; and he it fun her
Sec. 5. Quorum. Reso lved: I hat a lll<IJOn ty of the task force cc1nstitu tcs a quorum lot the
o f' it s business; <uld he it further

t nu t~action

Src. 6. Cnrnmittccs. Reso lved: I hat the task force cha ir m;ty establish conun illccs lo r thl:

purp<>sc of mak ing speci~ l stuthcs pursuant tu Its duties and may appoin t persons who arc ntlt
mcmhcrs of the task Ioree to serve on each commtllec as resource persons. Resource persons urc
voting members or the committees to whtch they arc appOinted. Commtuce~ may meet w ith the
Crcquc;ncy needed to accompl ish tlw purpos1.·s o f ~his resolve; anu be it funhcr

Sec. 7. Duties. Resolved: That the task force

sh~ ll :

I . Revi ew statistica l and quali tative data on the prc,·a lcnce <md incadcncc of cervical cancer in

Maine;

2.. Review preveDt ive strategies and new technologies. including newly introduced vaccines
and their effectiveness in preventing and contro l! ing the ri sk of cervical cancer, as well as their
relative costs;

J . Identify and examine the strengths and limitations of existing laws, regulations, programs
and serv ices regarding coverage and awareness of cervical cancer;
4. Consider reports and testimony fTOm indi,·iduals, local health departments, comnuUJitybased organ izations, voluntary health organizations and other public and private organizations
statewide lo learn more about their contributions to cervical cancer diagnosis. prevention and
treatment and their ideas for improving prevention. diagnosis and treatment in Maine;
5. Develop, in consuliation wi th Ihe Depanmem ofHealth and Human Servaces. a statewide
comprehensive cervical cancer prevention plan and stTategies tbr plan implemen tation and for
promoting the plan and awareness of the causes . .risk factors, prevention, early detection and
treatment of cervical cancer to the general pub he. state and local elected officials and various
pub lic und private organizations. associations, businesses, industries <Lnd agcncie.s; and

6. Recommend str.uegies for coordination and commun ication am<mg s tate and local agencies
and organizations regard ing their involvement in achieving the ~i ms of the cervica l cancer
preventton plan; and be it further

Sec. 8. Stan assistance. Resolved : ·n,at the Lcgisl~ t ive Council shal l provide necessary
StJffing services to the task force; and be ll further
Sec. 9. Compcnsn lion. Reso lved : That legisla tive members of the task force arc enti tl ed to
receive the legislat ive per diem. as de lined m the Maine Revised Statutes. Tille 3, section 2. and
reimbursemen t for tnovcl and other ncccss<try expenses f~1r their aucndancc ;tt authori«:ed
meetings of the t :1~k fo rce. Pub l•c mcmbc.:rs not otherwt<e cornpens:ned by thctr entp loycrs or
~lti tL'r cnti t i v~ that thcy rcpr.:scnt arc cottit lcd to receive reimbursement of necessary ex penses and.
upon'' demonstration of linaJlcial hard ship. u per diem eq ual to the legislative per diem tbr their
allcoulance Ill :1uthori1cd meetings of the task Ioree; and be 1t further
Sec. 10. Report. Reso lved: 'I h<1t, no Inter than December 7. 2005, the task force s hall suhmit
initia l report to the .Joint Standmg Comm Jitc.: on llcallh and Human Services und tho.:
(_jovernor. rh c task force IS not authon;,cd to meet from Dcccmbct 2 1. 2005 to Apnl 25. 2006 or
a11

to int roduce legis lation. The task force shal l submit its final report to the joint s tanding
conun ittt:c o f tl oe Lt:gislaturc havmg.rurisdttuon over health ;md human services matters by
November I, 2006. The joint standing commtllcC ofth.: Legislature ll<~Vingjunsdiclion over
health and human services rnauers in the First Regular Session of the 123rd LegislaLUrc rnay
repon out leg•s lahon on cervica l c;mcer preven tion, dctecuon :md cducalion: and be it furtltcr
Sec. II. Ta~ k rurcc rundi ng. Reso lved : That the task force shall seck outside funds to Cully
fund al l costs of the task force. If sufficient outside li.utd ing has not been received hy Scptembt:r
15, 2005 to fltlly fund al l costs of the task force, no meetings arc authoti zed a nd no expenses of
any kind may be incurred or reimbursed. Contributions to suppon the work of the task Ioree may
not be accepted ii·om any party having pecuniary or other vested interest in the omcome of the
matters being studied. Any person, other than a state agency, desiring to make a IinaLlCia.l or inkind contribution must ccnify to the Legislative Council that il has no pecuniary or other vested
interest in the outcome of the smdy. Such certification must be made tn the manner prescribed by
lltc Legislative Council. All contributions are subject to approval by the Legislative Council. All
funds accepted must be forwarded to the Executi,·e Director of the Legislative Council along
with an accounti ng record that includes the amount of funds, the date the funds were received,
ti·om whom the funds were received and the purpose of and any limit~tion on U1c usc of those
funds. The Executive Director of tlte Legislati ,·e Council shall administer any funds received by
the task force. ·ntc executive director shall notify the chair of the task force when suffic ienl
fttnding has been received; and be it funher
Sec. 12. Appropr·iations and a lloca tio ns. R esolved: That the following appropriations and
allocations are made.
LEGISLATURE
Mi~cellan eoo s

Studies 044 4
lnitiauvc: Provides an allocation of Other Special Revenue Funds in the C\'Cnt outside funding is collected to suppo rt
Ute acuvitJCS of lhc Task Force to Srudy CerVICal Cancer Prcvcnt10n. Detection and Education. Jf sufficient outside
fwJding ~as not been rce''"·cd by September 15, 2005 to fully fund all costs of the tnsk force. no meetings are
authonzcd nud no expenses of any kind may be IJ)eurrcd or rcomburscd.

OHrE R S l' F.CI AI. REVEl\ l ff:
FUNDS 2005-Q(, 2006-07
Persona I Scl\'ltcs $880 5880
All Olloc• $3.600 $3.600
()Til ER ~I'Er' I AI.)U,V I :-JUE
1' 1fNr>S "I 0"1 A I
$4,4811

l~ mugcn c~·

$4 ,480

clausr. In ,-icw or the emergency citcclmthc prcmnblc.this resolve takes effect

wiK·n approved.
Eni..-cti vc J unc 21, 2005

APPE DlX B
Task Force Membership List

Task Force to Study Cervical C:ancer Prevention, Detection and
Education
Res olve 2005, Ch. 121

Appointment(s) by the President
Sen . Nancy B. Sullivan - Chair
20 Westwood Omre
Biddeford. ME 04005
207 202-5594

Senate Member

Kolawolo Adownlo Bankolo M.D .. M.S.
Am<:m d;> Lane. l ol # 10
PO Box 5642
Ellsworth, ME 04605

Ropresentong Communoca~ons Consull<!nls

Dinn Colo BSN, RN, CPAN
9 Lemon Stroot
Ve<lll<l. ME 04401

Represenhng Locensod Regostorcd Nursc•s

J onnthnn T. Fnnburg M.D., M.P.H.
PO Oox 1420
Ell$worth, ME 04005

Rcproscntong the Amcrocan Ac;oclumy of Podlatnc~

MichOol A. Jonos M.D.
152 Morton Road
Yarmouth. ME 04096

Ropoesenhn(lthe Maino Medocal Associallon

Evelyn G. Klellyka MSN , MS, FNP

Rcpresen11n9 a Women's Health Orga1111<1tion

Family Planning Assoc. of ME
P 0 Box587
Augusla. ME 04332-0567
James A. Rnczok M.D., FACFP
489 State Sl, - Webber 1
Bangor, ME 04401
207 945-6573

Representong the Academy ol Famly Physioans

Appolnlment(s) by the Speaker
Rep . Usa T. Marrache - Chair
109 S~ver Street
Waterville, ME 04901
207 861-0154

House Members

Rep. James J . Campbell Sr.
P.O. Box 29
West Newfield , ME 04095

House Members

Carrie Bolander, D.O.
24 M1les Center Way
Damariscotta. ME 04543

Representong the Maone Osteopathic Association

Bob Downs
RR 1.Box 1580
Pittsfield, ME 04967

Representong the Health Insurance Industry

Susan Miestoldt, M.D.
Maine Center for Cancer Medicine
100 u S . Roulo 1
Scarborough. ME 0407 4
207 885-7600

Representing the American Cancer Socoety (Oncologist)
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Janet Miles
PO Box 3205
Auburn, ME 04212-3205
James Wilberg, M.D.
35 Stapleford Drive
Falmouth, ME 04105

Representing Cervu:al Cancer Survivors

Representing the American College of Obstetricians &
Gynecologists

Medical Director, Maine Cancer Registry
Dr. Molly Schwenn, Medical Director
Maine Cancer Registry
State ~louse Station 11 4111 Floor. Key Plaz;~
Augusta, ME 04333
207 207-6945

Director. Mame Cancer Regfslly

Other
Sharon Jerome Program Director
MI3CHP. Key Plaza, 4th Floor
11 Stale House Station
Augusto , ME 04333
207 287·6895

Director. Mame Breast & Cerv•cal Health Program, DHHS
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APPENDIX C
Agenda for Nove mber 16, 2005 Meeting

Task Force to Study Cervical Cancer Prevention,
Detection and Education
~ovem ber

16,2005, 1:00pm to 4:00pm
Room 427, State House

AGENDA
I :(t()pm

Welcome and lntroducuons

I :JOprn

Overview of

2:00pm

Whun; arc we now'1 Ovcrvtcw of Cervical Canr.:cr lnctdcncc and Prevention ,
Lktcction and l:llucauon l11111ntl\ cs 111 M:unc
•
•

3:0(1prn

Force Lc•gislat ion. Duties and Requirements

Dr. :-v1olly Sch\\ cnH, Dm!ctor, Mamc Cancer Registry
Sharon Gerome. Dtrcctor, Maine Breast and Ccrvtcall lca lth l'rogr~m

l ~1sk Force Planning
o
o
o

4:00pm

1"11~k

Establishing Priorities and Goals
Developing Work Plan Schedule
Planning for Initial Report due December 2005

Adjournment

Next Meeting: Oecember J6. 2005 :at 1:OOpm in State House Room 427
Staff:
1\tcole Dube. Office of Policy and Legal Analysts. 287-1 670. ematl: !1!£9le.dube(ailegtslantre.maine.uov
Lucw Nixon. Office of Policy and Legal Analysis, 287-1670. cmatl: lucia.nixon@le!ili.Jill!'.Le.maine.gov

A PP END I X 0
Agenda fo r December 20, 2005 :\'1ecting

Task Force to Study Cervical Cancer Prevention,
Detection and Education
December 20, 2005, I ::IOpm to 4:30pm
Room ~27, S tate House

AGE DA
I ::lOpm

Int roduct1 ons

1:45pm

2:00pm

'1\:chno logy I.-sues !Jr Junes
• II PV /vacc111c de\'clopmcnt

•
•

Thin prep vs. convcntionnl p;tp
Women who arc screened but for whom screening fai Is

Wc~tem

2:30pm

Maine Cnmmumt) Action Program, "At Your Cervix ''
Saru I lares. 7n · Count1 /lealrh St•J-vtces

3:00pm

MaineCan: con:rasc of cer. ical cancer screeningilrealmcnl
Linda Schumadwr ami Mauro Howtlrd, fJN!IS

3:30pm

Repor1 !Jack on the Cervtca l Cancer Summi t, Rep. Marraclte

J:4;:ipm

lnil ial Report (Due December ~3)- Review draft

4:30pm

Adjoumment

.Staff:

Nicole Dube, Office or Policy and Legal Analysis, 287-1670, cmml: mcole.dube((i;lemslg_tur".m'!)n~.gQ.y
Lucia Nixon, Office of Polley and Leg.al Analysis, 287-1670. email: lucin.ni.,on@.kgi;;lattrre.mnine.gov

